Navigation Links
GeoVax Phase 2a Clinical Trial Completes Enrollment
Date:10/3/2011

orm of the HIV envelope protein can elicit neutralizing Ab for tier 2 viruses."

"The completion of enrollment for our phase 2a trial is an important milestone," said Robert  McNally, Ph.D., GeoVax's President and CEO. "We now look forward to completion of the inoculations and the unblinding of safety and immunogenicity results for the entire trial."

Patient enrollment for HVTN 205 was conducted at 11 clinical sites in North America and two sites in South America.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of Phase 2 testing and the extension of clinical testing to include a granulocyte macrophage-colony stimulating factor (GM-CSF) adjuvanted version of the vaccine.  GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

About the HVTN

The HIV Vaccine Trials Network (HVTN) is the largest worldwide clinical trials network dedicated to the d
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
2. GeoVax Labs, Inc. Announces Second Quarter Financial Results
3. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
4. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
5. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
6. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
7. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
8. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
9. GeoVax Labs Engages The Investor Relations Group
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
11. GeoVax Labs, Inc. Plans Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Radiation Oncology Solutions announced that it has ... medical linear accelerators at the John Theurer ... N.J. (Logo: http://photos.prnewswire.com/prnh/20101028/NE90717LOGO) ... which Varian designed to treat a moving ...
... YORK, Nov. 8, 2010 Reportlinker.com announces ... available in its catalogue: ... platforms, key players, and early pipeline candidates ... Therapeutic vaccines promise a new ...
Cached Medicine Technology:D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center 2D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 2Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 4Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 5Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 6Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 7Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 8Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 9
(Date:7/12/2014)... 12, 2014 Casinos in ... rising competition from international and online casinos. Revenue is ... the five years through 2014-15. Greater per capita gambling ... gaming services. Rises in discretionary income levels have also ... on non-essential items such as casino gambling services. Revenue ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
Breaking Medicine News(10 mins):Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Multi-year contract provides IP VPN service to eight sites nationwide, - Triples ... legacy ... solution, ROCHESTER, N.Y., ... provider of managed voice and data,networking solutions for businesses, today announced a ...
... Wash. March 17, 2008 The International Neuroinformatics ... Science announced today that the INCF will contribute infrastructure ... Institutes Allen Brain AtlasMouse Brain. Publicly available for ... Brain AtlasMouse Brain is a Web-based, genome-wide map of ...
... discovered what chemical in the eye triggers the dormant ... cells, a stem-like cell that can generate new retinal ... Investigative Ophthalmology and Visual Science (IOVS), offers new hope ... as macular degeneration and retinitis pigmentosa. , This ...
... On The Go,Healthcare, Inc. (OTC Bulletin Board: ... software and systems integrator,announced today that after more ... has sold its Value Added Reseller (,VAR,),business unit ... Board: FLIP). The,terms of the sale, in the ...
... from North Carolina State University have shown that silencing ... harmful carcinogens in cured tobacco leaves. , The finding ... with reduced amounts of cancer-causing agents. , NC ... Dr. Ramsey Lewis, assistant professor of crop science, teamed ...
... Neuroethics, in March 2008. Appearing three times a year, it ... related issues in the sciences of the mind. Springer ... all articles during 2008 and 2009. , Neuroethics will be ... the neuroscience of ethics. The journal will be highly ...
Cached Medicine News:Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 2Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 3Health News:INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 2Health News:INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 3Health News:Scientists successfully awaken sleeping stem cells 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Gene 'knockout' floors tobacco carcinogen 2Health News:Springer to publish new journal focusing on ethical issues in neuroscience 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: